Contemporary antiplatelet and anticoagulant therapies for secondary stroke prevention: a narrative review of current literature and guidelines
K Bhatia, LM Ladd, KH Carr, M Di Napoli… - Current Neurology and …, 2023 - Springer
Abstract Purpose of Review Stroke is a leading cause of death and disability worldwide. The
annual incidence of new or recurrent stroke is approximately 795,000 cases per year in the …
annual incidence of new or recurrent stroke is approximately 795,000 cases per year in the …
Perioperative stroke
JP Fanning, BCV Campbell, R Bulbulia… - Nature Reviews …, 2024 - nature.com
Ischaemic or haemorrhagic perioperative stroke (that is, stroke occurring during or within 30
days following surgery) can be a devastating complication following surgery. Incidence is …
days following surgery) can be a devastating complication following surgery. Incidence is …
Cerebrolysin for acute ischaemic stroke
LE Ziganshina, T Abakumova… - Cochrane Database …, 2023 - cochranelibrary.com
Background Cerebrolysin is a mixture of low‐molecular‐weight peptides and amino acids
derived from porcine brain, which has potential neuroprotective properties. It is widely used …
derived from porcine brain, which has potential neuroprotective properties. It is widely used …
Antiplatelet effect of ginkgo diterpene lactone meglumine injection in acute ischemic stroke: A randomized, double‐blind, placebo‐controlled clinical trial
C Chen, H Lv, L Shan, X Long, C Guo… - Phytotherapy …, 2023 - Wiley Online Library
This study was designed to evaluate antiplatelet effect and therapeutic effect of ginkgo
diterpene lactone meglumine injection (GDLI) in acute ischemic stroke (AIS) patients. In this …
diterpene lactone meglumine injection (GDLI) in acute ischemic stroke (AIS) patients. In this …
PAR4 antagonism in patients with coronary artery disease receiving antiplatelet therapies
J Nash, MN Meah, B Whittington… - … and Vascular Biology, 2024 - Am Heart Assoc
BACKGROUND: BMS-986141 is a novel potent highly selective antagonist of PAR (protease-
activated receptor) type 4. PAR4 antagonism has been demonstrated to reduce thrombus …
activated receptor) type 4. PAR4 antagonism has been demonstrated to reduce thrombus …
A comprehensive review of stroke-related signaling pathways and treatment in western medicine and traditional Chinese medicine
B Chen, W Jin - Frontiers in Neuroscience, 2023 - frontiersin.org
This review provides insight into the complex network of signaling pathways and
mechanisms involved in stroke pathophysiology. It summarizes the historical progress of …
mechanisms involved in stroke pathophysiology. It summarizes the historical progress of …
Association between aspirin and mortality in critically ill patients with atrial fibrillation: a retrospective cohort study based on mimic-IV database
M Zhang, Y Zuo, Z Jiao - Frontiers in Cardiovascular Medicine, 2024 - frontiersin.org
Background Atrial fibrillation (AF) is a prevalent issue among critically ill patients, and the
availability of effective treatment strategies for AF is limited. Aim The objective of this study …
availability of effective treatment strategies for AF is limited. Aim The objective of this study …
The Safety and Efficacy of Cangrelor in Endovascular Thrombectomy Compared with Glycoprotein IIb/IIIa Inhibitors
A Devarajan, S Gottiparthi, MT Caton, A Ouf, K Wu… - medRxiv, 2024 - medrxiv.org
Background: Cangrelor, an intravenous P2Y12-receptor inhibitor, is a reversible and short-
acting antithrombotic medication non-inferior to irreversible Glycoprotein IIb-IIIa inhibitors …
acting antithrombotic medication non-inferior to irreversible Glycoprotein IIb-IIIa inhibitors …
Antiplatelet Therapy or Not for Asymptomatic/Incidental Lacunar Infarction
AE Bilski, HJ Aparicio, J Gutierrez, FE de Leeuw… - Stroke, 2023 - Am Heart Assoc
Asymptomatic lacunar infarcts represent the most common incidental finding on brain
magnetic resonance imaging (MRI) in clinical practice. 1 The estimated prevalence is 7 …
magnetic resonance imaging (MRI) in clinical practice. 1 The estimated prevalence is 7 …
Les antiplaquettaires dans l'ischémie cérébrale aiguë: limites et perspectives
D Leys, D Deplanque - Bulletin de l'Académie Nationale de Médecine, 2024 - Elsevier
Résumé Objectif Identifier le bénéfice apporté par les antiplaquettaires en phase aiguë de
l'ischémie cérébrale, leurs risques, et les perspectives en termes d'efficacité et de sécurité …
l'ischémie cérébrale, leurs risques, et les perspectives en termes d'efficacité et de sécurité …